Compare · BDX vs MDGS
BDX vs MDGS
Side-by-side comparison of Becton Dickinson and Company (BDX) and Medigus Ltd. (MDGS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and MDGS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $52.78B, about 1603.5x MDGS ($32.9M).
- BDX has hit the wire 8 times in the past 4 weeks while MDGS has been quiet.
- BDX has more recent analyst coverage (25 ratings vs 0 for MDGS).
- Company
- Becton Dickinson and Company
- Medigus Ltd.
- Price
- $191.68-1.09%
- $2.48-1.98%
- Market cap
- $52.78B
- $32.9M
- 1M return
- +5.72%
- -
- 1Y return
- +0.32%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 8
- 0
- Recent ratings
- 25
- 0
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Medigus Ltd.
Medigus Ltd., a medical device company, develops, produces, and markets minimally invasive endo-surgical tools with direct visualization technology in the United States, the United Kingdom, Europe, Asia, and internationally. It offers Medigus Ultrasonic Surgical Endostapler, an endoscopy system, which is used for the treatment of gastroesophageal reflux disease. The company also develops biological gels to protect patients against biological threats and reduce the intrusion of allergens and viruses through the upper airways and eye cavities. In addition, it develops, markets, and distributes software for internet users; develops and commercializes online and offline event planning software, as well as ticketing solutions; and operates online stores for the sale of various consumer products on the Amazon online marketplace. The company was incorporated in 1999 and is headquartered in Omer, Israel.
Latest BDX
- BD to Announce Financial Results for its Fourth Quarter and Full Year of Fiscal 2026
- BD and Global Health Leaders Call for Accelerated Maternal Life Saving Measures Worldwide
- BD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results
- BD Celebrates 65 Years of Manufacturing, Innovation and Community Partnership in Canaan
- BD Appoints Ferass Abuzaina as Worldwide President of Surgery
- BD and U.S. Government Launch Landmark Partnership to Expand U.S. Manufacturing and Strengthen America's Healthcare Resilience
- EVP, Chief Revenue Officer Feld Michael sold $13,961 worth of shares (76 units at $183.70) as part of a pre-agreed trading plan, decreasing direct ownership by 0.39% to 19,644 units (SEC Form 4)
- BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy
- Arthur Hu to Join BD as Chief Information and Digital Officer
- BD Advances Intelligent Robotics to Transform the Future of Pharmacy Care at Fairview
Latest MDGS
- Xylo Technologies: Viewbix Shares to Begin Trading on Nasdaq
- Xylo Technologies: Charging Robotics Successfully Installs Wireless EV Charging System in Automatic Parking Facility
- Xylo Technologies: Revoltz Secures First Institutional Client for PORTO EV Logistics Deployment
- Xylo Technologies: Revoltz Launches Commercial Phase of PORTO EV in Israel with First 50 Vehicles Delivered to Exclusive Distributor
- Xylo Technologies: Revoltz Receives Israeli Standards Institute Approval for PORTO EV Micro Vehicle
- Xylo Technologies: ParaZero Received Order from a Leading Tier-One Defense Company for 50 Drone Safety Systems
- Xylo Technologies: Revoltz to Launch an Innovative Three-Wheel Electric Cargo Bike for European and UK Markets
- Xylo Technologies Announces Plan to Implement ADS Ratio Change
- Xylo Technologies: Charging Robotics Lands Commercial Order for EV Wireless Charging Systems in Automatic Car Parks
- Xylo Technologies: Charging Robotics Secures First Commercial Order for EV Wireless Charging Systems in Automatic Car Parks